Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J. Sweeney, Kim Chi, Nicola Jane Lawrence et al.|The Lancet Oncology|2023Cited by 195
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Aron Goldhirsch, Kathryn P. Gray et al.|Journal of Clinical Oncology|2016Cited by 77